Reviewing the possible cure of drug-resistant hematologic malignancies by innovative cell-mediated immunotherapy using intentionally mismatched pre-activated donor lymphocytes
Main Article Content
Abstract
Preliminary data summarized in the present article provides support to a new treatment strategy based on cell-mediated immunotherapy of patients with multi-drug-resistant hematologic malignancies, based on a 2-step cell-mediated immunotherapy approach. First, attempting to induce a stage of minimal residual disease or minimizing tumor burden by conventional modalities, which can usually be accomplished at an early stage of the disease. Next, apply innovative cell-mediated immunotherapy by mismatched pre-activated killer cells following mild immunosuppressive conditioning. Out of a total of 33 patients with different drug-resistant hematologic malignancies, 23 accomplished complete remission and 6 observed for more than 5 years with no further treatment are probably cured. Using pre-activated mismatched killer cells was based on short-term circulation of multi-potent cancer killer cells including a mixture of T, NK & NKT cells, could result in most effective cytoreduction of all drug-resistant malignant cells, possibly even accomplishing cure, with no need for allogeneic stem cell transplantation, thus avoiding the hazardous risks of acute and chronic graft-vs-host disease. Our working hypothesis supported by pre-clinical and preliminary clinical investigations confirms the feasibility to cure patients with different hematologic malignancies considered otherwise incurable using mismatched pre-activated killer cells following mild immunosuppressive conditioning. Our suggestion that our innovative cell-mediated immunotherapy could eliminate fully resistant malignant cells in patients with a broad range of otherwise incurable hematologic malignancies needs to be confirmed by prospective randomized clinical trials.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-vs-leukemia without myeloablative therapy. Blood 1997;89(12):4531-4536.
3. Weiden PL, Sullivan KM, Fluornoy N et al. Anti-leukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. New Engl J Med 1981;304:1529-1533.
4. Bacigalupo A, Van Lint MT et al. Increased risk of leukemia relapse with high dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991;77(7):1423-1428.
5. Waldmann H, Polliack A, Hale G et al. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 1984;2:483-485.
6. Slavin S, Or R, Naparstek E, Cividalli G et al. New approaches for prevention of rejection and graft vs host disease (GVHD) in clinical bone marrow transplantation (BMT). Is J Med Sci 1986;22:264-267.
7. Slavin S, Cividalli G, Brautbar C et al. The use of CAMPATH-1 for prevention of graft vs host disease (GVHD) and total lymphoid irradiation (TLI) for abrogation of host resistance to T-cell depleted allografts. J Cell Biochem 1986;suppl 10D:235.
8. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995;23:1553-1562.
9. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation. Blood 1996;87(6):2195-2204.
10. Naparstek E, Or R, Nagler A et al. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor’s peripheral blood lymphocytes for prevention of relapse. Brit J Haematol 1995;89:506-515.
11. Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell 2017;168 (4):724-740.
12. Park JH, Riviere I, Gonen M et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. The New Eng J Med 2018;8(8):958-971.
13. Ludwig H, Terpos E, an de Dong N et al. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol 2023;24(6):e255-e269.
14. Slavin S, Ackerstein A, Or R et al. Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study. Cancer Immunol Immunother. 2010;59(10):1511-1519.
15. Pugatsch T, Oppenheim A, Slavin S. Improved single-step PCR assay for sex identification post-allogeneic sex-mismatched BMT. Bone Marrow Transplant 1996;17:273-275.
16. Slavin S. Allogeneic cell-mediated immunotherapy at the stage of minimal residual disease following high-dose chemotherapy supported by autologous stem cell transplantation. Acta Haematologica. 2005;114:214-220.
17. Slavin S. Immunotherapy with cure potential of multi-drug resistant hematologic malignancies using IL-2 preactivated intentionally mismatched donor lymphocytes J Cancer Res Clin Oncol. 2023;149(11):9277-9284.
18. Weiden PL, Fluornoy N, Sanders JE et al. Anti-leukemic effect of graft-versus-host disease contributes to /improved survival after allogeneic marrow transplantation. Transplantation 1981;13: 248-251.
19. Sullivan KM, Weiden PL, Storb R et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989;73:1720-1726.
20. Horowitz M, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555-562.
21. Higano CS, Brixey M, Bryant EM. Durable complete remission of acute non-lymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect. Transfusion 1990;50:175-178.
22. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462-2465.
23. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for blood and marrow transplantation. Blood 1995;86:2041-2050.
24. Collins RH, Shpilberg O, Drobyski WR et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15:433-444.
25. Porter DL, Roth MS, McGarigle C et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. New Engl J Med 1994;330:100-106.
26. Mackinnon S, Papadopoulos EB, Carabassi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995;86:1261-1268.
27. Weiss L, Weigensberg M, Morecki S et al. Characterization of effector cells of graft vs leukemia (GVL) following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia (BCL1). Cancer Immunol Immunother 1990;31:236-242.
28. Weiss L, Lubin I, Factorowich Y et al. Effective graft vs leukemia effects independent of graft vs host disease after T-Cell depleted allogeneic bone marrow transplantation in a murine model of B Cell leukemia/lymphoma. Role of cell therapy and rIL-2. J Immunol 1994;153(6):2562-2567.
29. Ljunggren HG, Karre K. In search of the “missing self’:MHC molecules and NK cell recognition. Immunology Today 1990;11:237-244.
30. Slavin S. Immunotherapy of cancer with alloreactive lymphocytes. Lancet Oncology 2001; 2:491-498.
31. Slavin S. Cancer immunotherapy with alloreactive lymphocytes. New Engl J Med 2000:343(11);802-803.